TP53 and acute myeloid leukemia: In an effort towards the design of novel therapeutics for hematological malignancies, we investigated several structurally diverse classes of compounds that can selectively downregulate the geranylgeranylation of small GTPases by directly inhibiting the biosynthesis of GGPP.16–18 In this report, we provide clear evidence that inhibition of GGPPS with one of our compound, CML-07–119 (Fig. 2) leads to inhibition of AML cell viability in a small panel of AML cells that include cells with TP53 mutations.